Molecular & Cellular Toxicology

The Korean Society of Toxicogenomics and Toxicoproteomics (대한독성유전 단백체학회)
권호 표지

The Inhibitory Effect of Pioglitazone on Agonist-dependent Vascular Contractility

  • Je, Hyun-Dong (Department of Pharmacology, College of Pharmacy, Catholic University of Daegu) ;
  • Cha, Sung-Jae (Department of Surgery, College of Medicine, Chung-Ang University) ;
  • Jeong, Ji-Hoon (Department of Pharmacology, College of Medicine, Chung-Ang University)
  • Published : 2008.03.31
Download PDF
⟨ Previous Next ⟩

Abstract

The present study was undertaken to determine whether pioglitazone treatment influences on the agonist-induced vascular smooth muscle contraction and, if so, to investigate the related mechanism. The measurement of isometric contractions using a computerized data acquisition system was combined with molecular experiments. Pioglitazone decreased Rho-kinase activating agonist-induced contraction but not phorbol ester-induced contraction suggesting the least involvement of $Ca^{2+}$-independent thin filament regulation of contractility. Furthermore, pioglitazone decreased thromboxane $A_2$ mimeticinduced phosphorylation of MYPT1 at Thr855, the newly-highlighted site, instead of Thr696. In conclusion, this study provides the evidence and possible related mechanism concerning the vasorelaxing effect of pioglitazone as an antihypertensive on the agonist-induced contraction in rat aortic rings regardless of endothelial function.

Keywords

References

  1. Uemura, S. et al. Diabetes mellitus enhances vascular matrix metalloproteinase activity: role of oxidative stress. Circ Res 88:1291-1298 (2001) https://doi.org/10.1161/hh1201.092042
  2. Senses, V. et al. Effect of 5-aminoimidazole-4-carboxamide riboside (AICA-r) on isolated thoracic aorta responses in streptozotocin-diabetic rats. J Basic Clin Physiol Pharmacol 12:227-248 (2001)
  3. Yki-Jarvinen, H. Thiazolidinediones. N Engl J Med 351:1106-1118 (2004) https://doi.org/10.1056/NEJMra041001
  4. Tack, C. J. & Smits, P. Thiazolidinedione derivatives in type 2 diabetes mellitus. Neth J Med 64:166-174 (2006)
  5. Waugh, J. et al. Pioglitazone: a review of its type 2 diabetes mellitus. Drugs 66:85-109 (2006) https://doi.org/10.2165/00003495-200666010-00005
  6. Giles, T. D. & Sander, A. G. Effect of thiazolidinediones on blood pressure. Curr Hypertens Rep 9:332-337 (2007) https://doi.org/10.1007/s11906-007-0060-0
  7. Marx, N. et al. Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ Res 83:1097-1103 (1998) https://doi.org/10.1161/01.RES.83.11.1097
  8. Marx, N. et al. PPARgamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARgamma as a potential mediator in vascular disease. Arterioscler Thromb Vasc Biol 19:546-551 (1999) https://doi.org/10.1161/01.ATV.19.3.546
  9. Somlyo, A. P. & Somlyo, A. V. Signal transduction and regulation in smooth muscle. Nature 372:231-236 (1994) https://doi.org/10.1038/372231a0
  10. Somlyo, A. P. & Somlyo, A. V. From pharmacomechanical coupling to G-proteins and myosin phosphatase. Acta Physiol Scand 164:437-448 (1998) https://doi.org/10.1046/j.1365-201X.1998.00454.x
  11. Uehata, M. et al. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 389:990-994 (1997) https://doi.org/10.1038/40187
  12. Sakurada, S. et al. $Ca^{2+}$-dependent activation of Rho and Rho-kinase in membrane depolarization-induced and receptor stimulation-induced vascular smooth muscle contraction. Circ Res 93:548-556 (2003) https://doi.org/10.1161/01.RES.0000090998.08629.60
  13. Kitazawa, T., Masuo, M. & Somlyo, A. P. Proteinmediated inhibition of myosin light-chain phospha-tase in vascular smooth muscle. Proc Natl Acad Sci USA 88:9307-9310 (1991)
  14. Gohla, A., Schultz, G. & Offermanns, S. Roles for G(12)/G(13) in agonist-induced vascular smooth muscle cell contraction. Circ Res 87:221-227 (2000) https://doi.org/10.1161/01.RES.87.3.221
  15. Leung, T., Manser, E., Tan, L. & Lim, L. A novel serine/threonine kinase binding the Ras-related RhoA GTPase which translocates the kinase to peripheral membranes. J Biol Chem 270:29051-29054 (1995) https://doi.org/10.1074/jbc.270.49.29051
  16. Matsui, T. et al. Rho-associated kinase, a novel serine/threonine kinase, as a putative target for small GTP binding protein Rho. EMBO J 15:2208-2216 (1996)
  17. Wilson, D. P. et al. Thromboxane $A_2$-induced contraction of rat caudal arterial smooth muscle involves activation of $Ca^{2+}$ entry and $Ca^{2+}$ sensitization: Rho-associated kinase-mediated phosphorylation of MYPT1 at Thr-855, but not Thr-697. Biochem J 389:763-774 (2005) https://doi.org/10.1042/BJ20050237
  18. Wooldridge, A. A. et al. Smooth muscle phosphatase is regulated in vivo by exclusion of phosphorylation of threonine 696 of MYPT1 by phosphorylation of Serine 695 in response to cyclic nucleotides. J Biol Chem 279:34496-34504 (2004) https://doi.org/10.1074/jbc.M405957200
  19. Tsai, M. H. & Jiang, M. J. Rho-kinase-mediated regulation of receptor-agonist-stimulated smooth muscle contraction. Pflugers Arch 453:223-232 (2006) https://doi.org/10.1007/s00424-006-0133-y
  20. Wier, W. G. & Morgan, K. G. $\alpha$1-Adrenergic signaling mechanisms in contraction of resistance arteries. Rev Physiol Biochem Pharmacol 150:91-139 (2003)
  21. Gerthoffer, W. T. et al. Activation of MAP kinases and phosphorylation of caldesmon in canine colonic smooth muscle. J Physiol 495:597-609 (1996) https://doi.org/10.1113/jphysiol.1996.sp021619
  22. Majithiya, J. B., Paramar, A. N. & Balaraman, P. R. Pioglitazone, a PPARgamma agonist, restores endothelial function in aorta of streptozotocin-induced diabetic rats. Cardiovasc Res 66:150-161 (2005) https://doi.org/10.1016/j.cardiores.2004.12.025